GIP and steatosis: In line with earlier studies demonstrating that subcutaneous administration of long-acting GIP analogues resulted in improved β-cell function and glycemic control [10], [11], [13], GIP Tg mice showed improved insulin sensitivity, glucose tolerance and β-cell function (Figures 1 and 2), as well as reduced steatosis.